Literature DB >> 1621817

Corticosterone 6 beta-hydroxylation correlates with blood pressure in spontaneously hypertensive rats.

C O Watlington1, L B Kramer, E G Schuetz, J Zilai, W M Grogan, P Guzelian, F Gizek, A C Schoolwerth.   

Abstract

Evidence for increased glucocorticoid 6 beta-hydroxylation (enhanced family 3A cytochrome P-450 activity) is found in certain reversible forms of human hypertension. This association was investigated in the spontaneously hypertensive rat (SHR). The proportion of injected [3H]corticosterone excreted in urine as 6 beta-[3H]OH-corticosterone was four- to fivefold higher in SHR than in control Wistar-Kyoto rats, before and after development of overt hypertension. Both hypertension and 6 beta-hydroxylation were inhibited by troleandomycin (a selective inhibitor of family 3A cytochromes P-450), consistent with a role for increased steroid 6 beta-hydroxylation in the genesis of hypertension in the SHR.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1621817     DOI: 10.1152/ajprenal.1992.262.6.F927

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  10 in total

1.  Effects of the glucocorticoid antagonist RU486 in spontaneously hypertensive and Sprague Dawley rats.

Authors:  A Soro; M Panarelli; C D Holloway; R Fraser; C J Kenyon
Journal:  J Endocrinol Invest       Date:  1995-12       Impact factor: 4.256

2.  CYP3A variation and the evolution of salt-sensitivity variants.

Authors:  E E Thompson; H Kuttab-Boulos; D Witonsky; L Yang; B A Roe; A Di Rienzo
Journal:  Am J Hum Genet       Date:  2004-10-18       Impact factor: 11.025

3.  Xanthine oxidase activity associated with arterial blood pressure in spontaneously hypertensive rats.

Authors:  H Suzuki; F A DeLano; D A Parks; N Jamshidi; D N Granger; H Ishii; M Suematsu; B W Zweifach; G W Schmid-Schönbein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-14       Impact factor: 11.205

Review 4.  CYP3A5 polymorphism, amlodipine and hypertension.

Authors:  Y-P Zhang; X-C Zuo; Z-J Huang; J-J Cai; J Wen; D D Duan; H Yuan
Journal:  J Hum Hypertens       Date:  2013-07-18       Impact factor: 3.012

5.  CYP3A5 as a candidate gene for hypertension: no support from an unselected indigenous West African population.

Authors:  D L Fisher; J Plange-Rhule; M Moreton; J B Eastwood; S M Kerry; F Micah; A Johnston; F P Cappuccio; I A M MacPhee
Journal:  J Hum Hypertens       Date:  2016-06-23       Impact factor: 3.012

6.  Influence of Genetic Admixture Components on CYP3A5*3 Allele-Associated Hypertension in Amerindian Populations From Northwest Mexico.

Authors:  Carlos Galaviz-Hernández; Blanca P Lazalde-Ramos; Ismael Lares-Assef; Alejo Macías-Salas; Margarita A Ortega-Chavez; Héctor Rangel-Villalobos; Martha Sosa-Macías
Journal:  Front Pharmacol       Date:  2020-05-11       Impact factor: 5.810

Review 7.  PXR and 4β-Hydroxycholesterol Axis and the Components of Metabolic Syndrome.

Authors:  Janne Hukkanen; Jukka Hakkola
Journal:  Cells       Date:  2020-11-09       Impact factor: 6.600

8.  Antisense oligonucleotide development for the selective modulation of CYP3A5 in renal disease.

Authors:  Kevin A Lidberg; Andrew J Annalora; Marija Jozic; Daniel J Elson; Lu Wang; Theo K Bammler; Susanne Ramm; Maria Beatriz Monteiro; Jonathan Himmelfarb; Craig B Marcus; Patrick L Iversen; Edward J Kelly
Journal:  Sci Rep       Date:  2021-02-25       Impact factor: 4.379

9.  Top Three Pharmacogenomics and Personalized Medicine Applications at the Nexus of Renal Pathophysiology and Cardiovascular Medicine.

Authors:  Murielle Bochud; Michel Burnier; Idris Guessous
Journal:  Curr Pharmacogenomics Person Med       Date:  2011-12

10.  Association between urinary 6β-hydroxycortisol/cortisol ratio and CYP3A5 genotypes in a normotensive population.

Authors:  Naushad Rais; Arif Hussain; Yogesh Kumar Chawla; Krishan K Kohli
Journal:  Exp Ther Med       Date:  2012-11-29       Impact factor: 2.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.